Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077526 | 0.77 | ALDH1A1 (0.38) | TLR7KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL1078774 | 0.77 | TSHR (0.36) | TLR7KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL1080379 | 0.77 | NLRP3 (0.41) | TLR7KDM4ETDP1L3MBTL1 | |
| SCHEMBL1059505 | 0.75 | L3MBTL1 (0.54) | KDM4ETDP1L3MBTL1MAPK1RECQL | |
| SCHEMBL1054301 | 0.74 | HSP90AA1 (0.46) | TLR7 | |
| SCHEMBL1788256 | 0.74 | CYP3A4 (0.38) | TLR7KDM4ETDP1MAPK1 | |
| SCHEMBL1055154 | 0.72 | MAPK1 (0.53) | KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL1061420 | 0.71 | MAPT (0.42) | TLR7KDM4ETDP1L3MBTL1MAPK1 | |
| SCHEMBL1059523 | 0.71 | HSP90AA1 (0.43) | TLR7KDM4E | |
| SCHEMBL1058303 | 0.71 | TLR7 (0.39) | TLR7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| EP-2273882-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | Poniard Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | TLR7 4464/4885KDM4E 3340/4885TDP1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.